Effects of Cilostazol on Dizocilpine-induced Hyperlocomotion and Prepulse Inhibition Deficits in Mice

This study was undertaken to examine the effects of cilostazol, a selective inhibitor of type III phosphodiesterase (PDE), on hyperlocomotion and prepulse inhibition (PPI) deficits in mice after a single administration of the N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine. A single oral administration of cilostazol (0.1 and 0.3 mg/kg) significantly attenuated hyperlocomotion and PPI deficits in mice after the administration of dizocilpine (0.1 mg/kg, subcutaneously). This study suggests that cilostazol may have antipsychotic activity in animal models of schizophrenia. Therefore, cilostazol may be a potential therapeutic drug for schizophrenia, given that cilostazol has been safely used throughout the world.